CN103044402B - 埃索美拉唑钠合成生产方法 - Google Patents
埃索美拉唑钠合成生产方法 Download PDFInfo
- Publication number
- CN103044402B CN103044402B CN201210590638.6A CN201210590638A CN103044402B CN 103044402 B CN103044402 B CN 103044402B CN 201210590638 A CN201210590638 A CN 201210590638A CN 103044402 B CN103044402 B CN 103044402B
- Authority
- CN
- China
- Prior art keywords
- add
- stir
- esomeprazole sodium
- methoxy
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960000496 esomeprazole sodium Drugs 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 16
- RYXPMWYHEBGTRV-JIDHJSLPSA-N sodium;5-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-3-ide Chemical compound [Na+].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-JIDHJSLPSA-N 0.000 title claims abstract 18
- 230000002194 synthesizing effect Effects 0.000 title 1
- 238000003756 stirring Methods 0.000 claims abstract description 58
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 25
- 239000012043 crude product Substances 0.000 claims abstract description 24
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940043279 diisopropylamine Drugs 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 10
- YSAVZVORKRDODB-WDSKDSINSA-N diethyl tartrate Chemical compound CCOC(=O)[C@@H](O)[C@H](O)C(=O)OCC YSAVZVORKRDODB-WDSKDSINSA-N 0.000 claims abstract description 9
- 230000035484 reaction time Effects 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 238000007670 refining Methods 0.000 claims abstract description 5
- 238000001291 vacuum drying Methods 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 111
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 48
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- 239000012065 filter cake Substances 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 13
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 9
- 229910021641 deionized water Inorganic materials 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- XURCIPRUUASYLR-UHFFFAOYSA-N Omeprazole sulfide Chemical compound N=1C2=CC(OC)=CC=C2NC=1SCC1=NC=C(C)C(OC)=C1C XURCIPRUUASYLR-UHFFFAOYSA-N 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
- 229960000583 acetic acid Drugs 0.000 claims description 4
- -1 filter Substances 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000004042 decolorization Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 1
- 229960000935 dehydrated alcohol Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 150000003568 thioethers Chemical class 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 3
- 238000001308 synthesis method Methods 0.000 abstract description 3
- HEZSBUNWERXKSX-UHFFFAOYSA-N 1-methylsulfanylbenzimidazole Chemical compound C1=CC=C2N(SC)C=NC2=C1 HEZSBUNWERXKSX-UHFFFAOYSA-N 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229960004770 esomeprazole Drugs 0.000 description 8
- 238000009835 boiling Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- LCJDHJOUOJSJGS-UHFFFAOYSA-N 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridin-1-ium;chloride Chemical compound Cl.COC1=C(C)C=NC(CCl)=C1C LCJDHJOUOJSJGS-UHFFFAOYSA-N 0.000 description 3
- KOFBRZWVWJCLGM-UHFFFAOYSA-N 5-methoxy-1,3-dihydrobenzimidazole-2-thione Chemical compound COC1=CC=C2NC(S)=NC2=C1 KOFBRZWVWJCLGM-UHFFFAOYSA-N 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- 229960000381 omeprazole Drugs 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229920000333 poly(propyleneimine) Polymers 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- JLIDVCMBCGBIEY-UHFFFAOYSA-N 1-penten-3-one Chemical compound CCC(=O)C=C JLIDVCMBCGBIEY-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 102000006270 Proton Pumps Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- FNENWZWNOPCZGK-UHFFFAOYSA-N ethyl 2-methyl-3-oxobutanoate Chemical compound CCOC(=O)C(C)C(C)=O FNENWZWNOPCZGK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210590638.6A CN103044402B (zh) | 2012-12-31 | 2012-12-31 | 埃索美拉唑钠合成生产方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210590638.6A CN103044402B (zh) | 2012-12-31 | 2012-12-31 | 埃索美拉唑钠合成生产方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103044402A CN103044402A (zh) | 2013-04-17 |
| CN103044402B true CN103044402B (zh) | 2015-01-14 |
Family
ID=48057286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210590638.6A Active CN103044402B (zh) | 2012-12-31 | 2012-12-31 | 埃索美拉唑钠合成生产方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103044402B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103242295B (zh) * | 2013-05-14 | 2015-11-04 | 山东罗欣药业集团股份有限公司 | 埃索美拉唑钠晶型化合物及其合成方法 |
| CN104693177A (zh) * | 2013-12-09 | 2015-06-10 | 北大方正集团有限公司 | 一种埃索美拉唑钠的精制方法 |
| CN103755685B (zh) * | 2014-01-16 | 2015-03-25 | 山东科源制药有限公司 | 一种埃索美拉唑钠的纯化精制方法 |
| CN103739592A (zh) * | 2014-01-24 | 2014-04-23 | 山东科源制药有限公司 | 一种埃索美拉唑钠的生产方法 |
| CN104163814B (zh) * | 2014-05-27 | 2016-08-24 | 浙江新东港药业股份有限公司 | 一种高纯度5-甲氧基-2-((s)-((4-甲氧基-3,5-二甲基-2-吡啶基)甲基)亚磺酰基)-1h-苯并咪唑钠制备方法 |
| CN105418589B (zh) * | 2016-01-17 | 2017-09-26 | 青岛市中心医院 | 一种治疗消化系统疾病的埃索美拉唑镁三水合物制备方法 |
| CN106366070B (zh) * | 2016-08-10 | 2019-06-11 | 上海万巷制药有限公司 | 一种高纯度埃索美拉唑钠的制备方法 |
| CN107987058A (zh) * | 2017-11-28 | 2018-05-04 | 江苏中邦制药有限公司 | 一种艾司奥美拉唑钠杂质i的合成方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1157614A (zh) * | 1994-07-15 | 1997-08-20 | 阿斯特拉公司 | 取代的亚砜类化合物的合成方法 |
| CN101538264A (zh) * | 2008-03-19 | 2009-09-23 | 中国科学院成都有机化学有限公司 | 手性亚砜类化合物的制备新方法 |
| CN102584792A (zh) * | 2012-01-06 | 2012-07-18 | 南京优科生物医药研究有限公司 | 制备高纯度的埃索美拉唑盐的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102241670B (zh) * | 2011-04-28 | 2013-05-29 | 苏州特瑞药业有限公司 | 一种高纯度手性亚砜类化合物的制备方法 |
-
2012
- 2012-12-31 CN CN201210590638.6A patent/CN103044402B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1157614A (zh) * | 1994-07-15 | 1997-08-20 | 阿斯特拉公司 | 取代的亚砜类化合物的合成方法 |
| CN101538264A (zh) * | 2008-03-19 | 2009-09-23 | 中国科学院成都有机化学有限公司 | 手性亚砜类化合物的制备新方法 |
| CN102584792A (zh) * | 2012-01-06 | 2012-07-18 | 南京优科生物医药研究有限公司 | 制备高纯度的埃索美拉唑盐的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103044402A (zh) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103044402B (zh) | 埃索美拉唑钠合成生产方法 | |
| ES2320172T3 (es) | Procedimiento para la produccion de 5-(4-(4-(5-ciano-3-indolil)-butil)-1-piperazinil)-benzofuran-2-carboxamida. | |
| CN101429192A (zh) | 生产手性亚砜衍生物的新方法 | |
| CN106946849A (zh) | 一种右兰索拉唑及其制备方法与用途 | |
| CN104418841A (zh) | 一种光学纯雷贝拉唑及其钠盐的制备方法 | |
| CN105418581A (zh) | 琥珀酸曲格列汀的制备方法 | |
| CN116621728A (zh) | 氧代吡啶类化合物的新型制备方法及关键中间体 | |
| CN103897025B (zh) | 一种匹多莫德的制备方法 | |
| CN110240586A (zh) | 2,3-二氢-1H-苯并[f]色满-2-胺衍生物的制备方法 | |
| CN104829595A (zh) | 手性卟啉催化氧化制备埃索美拉唑钠新工艺 | |
| CN103554005A (zh) | 一种左旋5-羟基色氨酸的简便合成新方法 | |
| CN106866630A (zh) | 一种右兰索拉唑的制备方法 | |
| CN115557882A (zh) | 一种(R)-1-Boc-3-氨基哌啶的制备方法 | |
| TWI746110B (zh) | 氧氮雜卓類化合物的製備方法 | |
| CN113185440B (zh) | 一种医药中间体n-boc-3-吡咯啉的制备方法 | |
| CN101560204B (zh) | 一种制备抗高血压药物西拉普利中间体的方法 | |
| WO2015085827A1 (zh) | 一种西洛多辛及其中间体的制备方法 | |
| CN101481334B (zh) | 一种适于工业化生产的卡巴拉汀的制备方法 | |
| CN114736210A (zh) | 吗啡喃衍生物的一种晶型的制备方法 | |
| CN106632256A (zh) | 一种质子泵抑制剂的合成方法 | |
| CN115010703A (zh) | 一种立他司特吗啉盐及其制备方法和应用 | |
| CN103641772B (zh) | (2r,4r)-4-甲基哌啶-2-甲酸乙酯化合物的制备方法 | |
| CN108079294B (zh) | 一种二茂铁-镧系金属复合物及其制备方法和应用 | |
| CN107141325A (zh) | 落新妇苷衍生物及其制备方法 | |
| CN106632368A (zh) | 一种伊立替康盐酸盐的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zeng Peian Inventor after: Wu Feng Inventor after: Liu Donghua Inventor after: Zhang Hao Inventor after: Wu Jianmin Inventor after: Zhang Jing Inventor after: He Lian Inventor after: Liu Juan Inventor before: Zeng Peian Inventor before: Wu Feng Inventor before: Liu Donghua Inventor before: Zhang Hao Inventor before: Wu Jianming Inventor before: Zhang Jing Inventor before: He Lian Inventor before: Liu Juan |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CENG PEIAN WU FENG LIU DONGHUA ZHANG HAO WU JIANMING ZHANG JING HE LIAN LIU JUAN TO: CENG PEIAN WU FENG LIU DONGHUA ZHANG HAO WU JIANMIN ZHANG JING HE LIAN LIU JUAN |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Synthesis and production method of esomeprazole sodium Effective date of registration: 20210730 Granted publication date: 20150114 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211014 Granted publication date: 20150114 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Synthesis and production method of esomeprazole sodium Effective date of registration: 20211028 Granted publication date: 20150114 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021980011259 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20150114 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021980011259 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Synthesis and production method of esomeprazole sodium Granted publication date: 20150114 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2024980045611 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |